Global Dravet Syndrome Treatment Market (2018-2022) to Grow at a CAGR of 8.35% - ResearchAndMarkets.com

October 2, 2018

DUBLIN--(BUSINESS WIRE)--Oct 2, 2018--The “Global Dravet Syndrome Treatment Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Dravet Syndrome Treatment Market is projected to grow at a CAGR of 8.35% during the period 2018-2022.

One trend affecting this market is the increased use of new generation drugs. With the increase in R&D of third-generation drugs, the uptake of new generation drugs is higher than the earlier generation drugs.

According to the report, one driver influencing this market is the rising number of strategic alliances. Several leading pharmaceutical companies are entering into partnerships to develop effective drugs for the treatment of dravet syndrome.

Further, the report states that one challenge affecting this market is the low awareness. Dravet syndrome is a rare and a severe type of epilepsy in infants with low awareness across the world which is likely to hinder the growth of the market.Market TrendsIncreased Use of New Generation DrugsAdvances in Biomedical SciencesStrong Pipeline

Key Vendors

BiocodexEpygenix TherapeuticsGW PharmaceuticalsOPKO HealthZogenix

Key Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Market Sizing

6. Five Forces Analysis

7. Pipeline Landscape

8. Market Segmentation by Product

9. Customer Landscape

10. Regional Landscape

11. Decision Framework

12. Drivers and Challenges

13. Market Trends

14. Vendor Landscape

15. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/3636zp/global_dravet?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005521/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/02/2018 07:30 AM/DISC: 10/02/2018 07:30 AM


Update hourly